In the new study, the lab has conducted the first large - scale whole genome sequencing study of asthma drug response in African Americans and Latino children in an effort to pin down the genetic factors contributing to
reduced albuterol response more precisely than possible in previous association studies.
These results reveal new risk markers in the genome that could be used to predict which children are likely to respond poorly to
albuterol and other current first - line anti-asthma drugs, and to guide the development of new therapies that will be more effective and
reduce the outsize burden of mortality in minority populations.